

THOMAS F. MCINERNEY
(212) 415-9215

December 7, 1998

Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Attn: Filing Desk

Re: Enzon, Inc.- Current Report on Form 8-K

Ladies and Gentlemen:

On behalf of our client Enzon, Inc. (the "Company"), we are transmitting electronically the Company's Current Report on Form 8-K (the "Form 8-K") dated November 20, 1998.

Please note that the Form 8-K filed herewith contains a conformed signature and that an original, manual signature will be retained in the Company's records for five (5) years.

Very truly yours,

/s/THOMAS F. MCINERNEY
Thomas F. McInerney

cc: Kenneth J. Zuerblis

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 20, 1998

ENZON, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
or incorporation)

0-12957
(Commission
File Number)

22-2372868
(IRS EMPLOYER
Identification)

20 Kingsbridge Road, Piscataway, New Jersey
(Address of principal executive offices)

08854
(Zip Code)

Registrant's telephone number, including area code

(732) 980-4500

(Former name or former address, if changed since last report)

Item 5. Other Events

Schering-Plough Corporation has advanced PEG-INTRON A(R), a long-acting dose formulation of Schering-Plough's INTRON(R) A, into Phase III clinical trials for chronic myelogenous leukemia.

PEG-INTRON A is in Phase III clinical trials for hepatitis C and malignant melanoma and is in early phase clinical trials for solid tumors, as well as in combination with REBETOL (R) for hepatitis C.

Except for the historical information herein, the matters discussed in this Form 8-K include forward-looking statements that may involve a number of risks and uncertainties. Actual results may vary significantly based upon a number of factors which are described in the Company's Form 10-Ks, Form 10-Qs and Form 8-Ks on file with the SEC, including without limitation, risks in obtaining and maintaining regulatory approval for expanded indications, market acceptance of an continuing demand for Enzon's products and the impact of competitive products and pricing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 7, 1998

ENZON, INC.
(Registrant)

By: /s/ Kenneth J. Zuerblis

Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial Officer (Principal
Financial Officer and Principal
Accounting Officer)